• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    1/12/22 5:34:29 PM ET
    $ABEO
    $ARDS
    $BMRA
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABEO alert in real time by email

    Gainers

    • Biomerica (NASDAQ:BMRA) stock increased by 10.2% to $4.95 during Wednesday's after-market session. The market value of their outstanding shares is at $61.9 million. As per the news, the Q2 earnings report came out today.
    • Puma Biotechnology (NASDAQ:PBYI) stock rose 8.39% to $2.84. At the close, Puma Biotechnology's trading volume reached 501.0K shares. This is 72.2% of its average volume over the last 100 days. The market value of their outstanding shares is at $116.1 million.
    • Aridis Pharmaceuticals (NASDAQ:ARDS) stock increased by 7.94% to $1.63. The company's market cap stands at $22.9 million.
    • Scopus BioPharma (NASDAQ:SCPS) shares rose 5.92% to $1.61. The company's market cap stands at $33.9 million.
    • Durect (NASDAQ:DRRX) stock rose 5.7% to $0.8. Trading volume for this security closed at 188.6K, accounting for 26.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $182.0 million.
    • Abeona Therapeutics (NASDAQ:ABEO) shares rose 5.31% to $0.31. Today's trading volume for this security ended up closing at 632.8K shares, which is 23.2 percent of its average volume over the last 100 days. The company's market cap stands at $45.0 million.

    Losers

    • electroCore (NASDAQ:ECOR) stock fell 10.4% to $0.79 during Wednesday's after-market session. This security traded at a volume of 1.2 million shares come close, making up 186.8% of its average volume over the last 100 days. The company's market cap stands at $55.7 million.
    • Vaxcyte (NASDAQ:PCVX) stock fell 9.1% to $20.0. The company's market cap stands at $1.0 billion.
    • NexGel (NASDAQ:NXGL) shares fell 3.66% to $3.16. The company's market cap stands at $17.5 million.
    • Immuron (NASDAQ:IMRN) stock decreased by 2.88% to $3.72. Today's trading volume for this security ended up closing at 159.5K shares, which is 365.1 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $21.1 million.
    • Recro Pharma (NASDAQ:REPH) shares declined by 2.8% to $1.74. The market value of their outstanding shares is at $81.1 million.
    • Prothena Corp (NASDAQ:PRTA) stock decreased by 2.78% to $36.43. This security traded at a volume of 56.2K shares come close, making up 15.0% of its average volume over the last 100 days. The company's market cap stands at $1.6 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABEO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABEO
    $ARDS
    $BMRA
    $DRRX

    CompanyDatePrice TargetRatingAnalyst
    Vaxcyte Inc.
    $PCVX
    1/7/2026$90.00 → $110.00Buy
    Needham
    Vaxcyte Inc.
    $PCVX
    9/12/2025$38.00Neutral
    Goldman
    Abeona Therapeutics Inc.
    $ABEO
    6/2/2025$19.00Outperform
    Oppenheimer
    Prothena Corporation plc
    $PRTA
    5/28/2025$4.00Neutral → Underperform
    BofA Securities
    Prothena Corporation plc
    $PRTA
    5/27/2025Outperform → Perform
    Oppenheimer
    Prothena Corporation plc
    $PRTA
    5/27/2025$6.00Buy → Hold
    Jefferies
    Prothena Corporation plc
    $PRTA
    5/27/2025Overweight → Neutral
    Cantor Fitzgerald
    Vaxcyte Inc.
    $PCVX
    4/22/2025Overweight
    Cantor Fitzgerald
    More analyst ratings

    $ABEO
    $ARDS
    $BMRA
    $DRRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for POSIMIR

    Submission status for DURECT CORP's drug POSIMIR (ORIG-1) with active ingredient BUPIVACAINE has changed to 'Approval' on 02/01/2021. Application Category: NDA, Application Number: 204803, Application Classification: Type 3 - New Dosage Form

    2/2/21 7:24:30 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    $ARDS
    $BMRA
    $DRRX
    SEC Filings

    View All

    SEC Form PRE 14A filed by Puma Biotechnology Inc

    PRE 14A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)

    4/7/26 5:11:29 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abeona Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - ABEONA THERAPEUTICS INC. (0000318306) (Filer)

    4/7/26 8:35:30 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by NexGel Inc

    10-K - NEXGEL, INC. (0001468929) (Filer)

    3/31/26 5:31:11 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    $ABEO
    $ARDS
    $BMRA
    $DRRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham reiterated coverage on Vaxcyte with a new price target

    Needham reiterated coverage of Vaxcyte with a rating of Buy and set a new price target of $110.00 from $90.00 previously

    1/7/26 8:03:12 AM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Vaxcyte with a new price target

    Goldman initiated coverage of Vaxcyte with a rating of Neutral and set a new price target of $38.00

    9/12/25 7:53:21 AM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer resumed coverage on Abeona Therapeutics with a new price target

    Oppenheimer resumed coverage of Abeona Therapeutics with a rating of Outperform and set a new price target of $19.00

    6/2/25 8:44:24 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    $ARDS
    $BMRA
    $DRRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference

    SAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 2:15 p.m. ET / 11:15 a.m. PT. A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company's website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference. About Vaxcyte Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences

    4/7/26 4:05:00 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors

    CLEVELAND, April 07, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced the appointment of Keith A. Goldan as a new independent member to its Board of Directors, effective as of April 1, 2026. Mr. Goldan will also serve as Chairman of Abeona's Audit Committee. Mr. Goldan brings more than two decades of financial leadership experience across publicly traded commercial-stage biotechnology and specialty pharmaceutical companies. His appointment to the Board of Directors reflects Abeona's continued focus on strengthening its leadership team to advance both strategic and financial objectives. "On behalf of the Board, we are delighted to welcome Keith to Abeona," sa

    4/7/26 8:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    electroCore Announces First Patient Enrollment in Investigator-Led Study of gammaCore™ nVNS for PTSD

    ROCKAWAY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the enrollment of the first eight patients in a clinical study being conducted by Acacia Clinics in collaboration with the Vagus Nerve Society. As previously announced, the study is designed to evaluate the safety and effectiveness of electroCore's gammaCore™ non-invasive vagus nerve stimulation (nVNS) device as an adjunctive treatment for symptoms associated with PTSD. The study is expected to enroll up to 40 adult participants and will assess outcomes over a 12-week treatment period. The primary safety endpoint is the incide

    4/7/26 8:00:00 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ABEO
    $ARDS
    $BMRA
    $DRRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Goldan Keith A.

    4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)

    4/7/26 8:47:16 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Goldan Keith A.

    3 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)

    4/7/26 8:45:26 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Wassil Jim

    4 - Vaxcyte, Inc. (0001649094) (Issuer)

    4/3/26 4:06:08 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    $ARDS
    $BMRA
    $DRRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Goldberger Daniel S bought $4,840 worth of shares (1,000 units at $4.84), increasing direct ownership by 0.34% to 292,565 units (SEC Form 4)

    4 - electroCore, Inc. (0001560258) (Issuer)

    12/3/25 7:00:20 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Large owner Asen R Scott bought $11,357 worth of shares (5,917 units at $1.92), increasing direct ownership by 0.22% to 2,672,529 units (SEC Form 4)

    4 - DURECT CORP (0001082038) (Issuer)

    8/26/25 3:41:18 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Asen R Scott bought $386,666 worth of shares (204,220 units at $1.89), increasing direct ownership by 5% to 2,666,612 units (SEC Form 4)

    4 - DURECT CORP (0001082038) (Issuer)

    8/22/25 6:10:18 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    $ARDS
    $BMRA
    $DRRX
    Leadership Updates

    Live Leadership Updates

    View All

    Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors

    CLEVELAND, April 07, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced the appointment of Keith A. Goldan as a new independent member to its Board of Directors, effective as of April 1, 2026. Mr. Goldan will also serve as Chairman of Abeona's Audit Committee. Mr. Goldan brings more than two decades of financial leadership experience across publicly traded commercial-stage biotechnology and specialty pharmaceutical companies. His appointment to the Board of Directors reflects Abeona's continued focus on strengthening its leadership team to advance both strategic and financial objectives. "On behalf of the Board, we are delighted to welcome Keith to Abeona," sa

    4/7/26 8:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer

    BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jane Wright-Mitchell, Pharm.D., J.D., as Chief Legal Officer, effective immediately. "Jane has worked with Vera Therapeutics previously as a strategic legal consultant and brings a depth and breadth of experience in supporting companies through regulatory approvals, commercialization, and intellectual property management," said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. "As we near the potential launch of

    3/25/26 7:30:00 AM ET
    $PCVX
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

    Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 Experienced commercial team is expected to join NEXGEL, significantly expanding the Company's sales reach and operational capabilities LANGHORNE, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) pr

    3/10/26 8:45:00 AM ET
    $CELU
    $NXGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $ABEO
    $ARDS
    $BMRA
    $DRRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by DURECT Corporation

    SC 13G/A - DURECT CORP (0001082038) (Subject)

    11/19/24 5:10:25 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Abeona Therapeutics Inc.

    SC 13G/A - ABEONA THERAPEUTICS INC. (0000318306) (Subject)

    11/14/24 7:56:28 PM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vaxcyte Inc.

    SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)

    11/14/24 5:46:11 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    $ARDS
    $BMRA
    $DRRX
    Financials

    Live finance-specific insights

    View All

    NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity

    LANGHORNE, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the rescheduling of its fourth quarter and fiscal year 2025 financial results conference call to April 8, 2026 at 4:30 P.M. ET to provide additional time for the Company to provide shareholders with greater detail regarding its previously announced proposed transaction with Celularity Inc. The Company will file its Annual Report on Form 10-K for the year ended December 31, 2025, with the

    3/31/26 4:12:54 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st

    Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., March 25, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, after the market close on March 31, 2026. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day. Fourth Quarter and Full Year 2025 Financial Results Conf

    3/25/26 9:00:00 AM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    electroCore Announces Full Year 2025 Financial Results and Organizational Changes

    Record full year 2025 net sales of $32.0, an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription business and 97% increase in general wellness sales Announces the retirement of Dan Goldberger as Chief Executive Officer in addition to other key executive management changes Company to host a conference call and webcast today, March 19, 2026, at 4:30pm EDT ROCKAWAY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today announced full year 2025 financial results. Reported record full year of 2025 revenue of $32.0 million, an increase of a

    3/19/26 4:05:00 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ABEO
    $ARDS
    $BMRA
    $DRRX
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Stock Movement: Insider Purchase at electroCore Inc. on Jun 6

    **Analysis of Recent Insider Purchase at electroCore Inc.** An insider purchase was recently made at electroCore Inc. by Goldberger Daniel S on June 6, 2024. This transaction involved the purchase of $247,587 worth of shares, equating to 38,505 units at an average price of $6.43 per share. As a result of this purchase, Goldberger's direct ownership in the company increased by 18% to 249,565 units, as reported in the SEC Form 4 filing. Looking at the historical insider transactions at electroCore Inc., several interesting patterns emerge when analyzing the timing, price, volume, purchaser's role, and more. On August 8, 2023, Goldstein Julie Ann and Cuneo F Peter both filed SEC Form 4 report

    6/10/24 12:57:57 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care